<DOC>
	<DOCNO>NCT02799095</DOCNO>
	<brief_summary>To good understand safety tolerability ALKS 4230 human</brief_summary>
	<brief_title>A Study Effects ALKS 4230 Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>For Part A , subject histological cytological evidence solid tumor ; Part B , subject histological cytological evidence 1 follow solid tumor type : melanoma , renal cell carcinoma , ovarian cancer All subject must advance solid tumor return treatment establish approved therapy intolerant establish therapy Subjects enrol Part B must least 1 lesion may qualify target lesion Subject move around , Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 , estimate life expectancy least 3 month Subject must adequate hematologic reserve Subjects must adequate liver function Subjects must adequate kidney function Subjects must recover effect prior chemotherapy , immunotherapy , prior systemic anticancer therapy , radiotherapy surgery Subjects receive investigational agent must wait least 4 week Females childbearing potential must negative pregnancy test within 7 day start treatment Day 1 first dose administer . A female childbearing potential one undergone bilateral oophorectomy postmenopausal , define &gt; 45 year age without menstrual period 12 consecutive month Meets contraceptive requirement define protocol Additional criterion may apply Subject currently pregnant breastfeed , plan become pregnant study Subjects active infection fever &gt; /+ 38.5 degree C within 3 day first schedule day dose Cycle 1 Subjects active symptomatic central nervous system metastasis exclude . Subjects central nervous system metastasis eligible study metastasis treat surgery and/or radiation therapy , subject corticosteroid least 2 week subject neurologically stable Subjects mean QT interval correct Fridericia Correction formula value &gt; 470 msec ( female ) &gt; 450 msec ( male ) Subjects know hypersensitivity component ALKS 4230 Subjects require pharmacologic dos corticosteroid ; replacement dos , topical , ophthalmologic , inhalational steroid permit Subjects develop autoimmune disorder prior immunotherapy , include pneumonitis , nephritis , neuropathy Subjects concurrent uncontrolled illness , include mental illness substance abuse , may interfere ability subject cooperate participate study The subject know positive human immunodeficiency virus ( HIV ) , hepatitis B C Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>IL-2</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Solid tumor</keyword>
</DOC>